ALUNBRIG 180 MG
BRIGATINIB : 180 MG · DIN 02479222 · TAKEDA CANADA INC
Health Canada status: MARKETED
What is ALUNBRIG?
ALUNBRIG 180 MG contains BRIGATINIB : 180 MG. It is listed in the Health Canada Drug Product Database under DIN 02479222, held by TAKEDA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Aug-2018. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ALUNBRIG used for?
ALUNBRIG (brigatinib) is indicated as a monotherapy for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC). It is also indicated as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to an ALK inhibitor (crizotinib).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02479222 |
|---|---|
| Brand name | ALUNBRIG |
| Generic / active ingredient | BRIGATINIB : 180 MG |
| Manufacturer | TAKEDA CANADA INC |
| Strength | 180 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01ED04 BRIGATINIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Aug-2018 |
| Original market date | 2018-08-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
One-month initiation pack – 7 x 90 mg film-coated tablets and 21 x 180 mg film-coated tablets in a single outer carton box; 28 x 30 mg film-coated tablets; 28 x 90 mg film-coated tablets; 28 x 180 mg film-coated tablets
What can be used instead?
Other Canadian products sharing ATC code L01ED04 BRIGATINIB. 4 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALUNBRIG | 30 MG | TABLET | TAKEDA CANADA INC | MARKETED | DIN 02479206 |
| ALUNBRIG | 90 MG | TABLET | TAKEDA CANADA INC | MARKETED | DIN 02479214 |
| ALUNBRIG | 90 MG | KIT ; TABLET | TAKEDA CANADA INC | MARKETED | DIN 02479230 |
Who else supplies BRIGATINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BRIGATINIB appears in 50 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.